CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.


At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.

Our product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy. In BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials.

Click here to view our Executive Leadership.

Click here to view our Board of Directors.

Executive Leadership

Arthur Kuan

Chairman & Chief Executive Officer

Ambaw Bellete

President & Chief Operating Officer

Vijay Kasturi, MD

Chief Medical

Swapnil Bhargava

Chief Technical

Corleen Roche profile picture

Corleen Roche

Chief Financial

Corleen Roche profile picture

Josh Patterson, Esq.

General Counsel & Chief Compliance Officer

Board of Directors

Arthur Kuan

Chairman & Chief Executive Officer

Susan E. Graf, RPh, MBA

Senior Advisor & Entrepreneur in Residence, Locust Walk

Brian Liu

Managing Director, Longitude Capital

Jim Mulé, PhD

Director of Cell-based Therapies, Moffitt Cancer Center

Leonard Post, PhD

Chief Scientific Officer, Vivace Therapeutics

Simone Song

Senior Partner, ORI Capital

Victor Tong, Jr.

Managing Director, Decheng Capital